Patents by Inventor Glenn Dranoff

Glenn Dranoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12037583
    Abstract: The present invention is directed to genome editing systems, reagents and methods for immunooncology.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 16, 2024
    Assignees: Novartis AG, Intellia Therapeutics, Inc.
    Inventors: Ming-Wei Chen, Melissa Deck, Glenn Dranoff, Craig Stephen Mickanin, Reynald Lescarbeau, Celeste Richardson, Morag Helen Stewart, Yi Yang
  • Publication number: 20240190942
    Abstract: Methods and compositions for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising a dimeric NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. In some embodiments, the molecule further comprises a drug moiety (e.g., an IL15/Ra moiety). The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
    Type: Application
    Filed: November 10, 2023
    Publication date: June 13, 2024
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Glenn Dranoff, Ryan Sullivan, Matthew Vanneman
  • Patent number: 11998593
    Abstract: The present invention comprises compositions, methods, and devices for enhancing an endogenous immune response against a cancer. Devices and methods provide therapeutic immunity to subjects against cancer.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: June 4, 2024
    Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: Omar Abdel-Rahman Ali, David J. Mooney, Glenn Dranoff
  • Publication number: 20240139244
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein by administration of a cell comprising a chimeric antigen receptor that binds a B-Cell antigen and a chimeric antigen receptor which binds a tumor antigen.
    Type: Application
    Filed: April 28, 2023
    Publication date: May 2, 2024
    Inventor: Glenn Dranoff
  • Patent number: 11851472
    Abstract: Methods and compositions for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising a dimeric NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. In some embodiments, the molecule further comprises a drug moiety (e.g., an IL15/Ra moiety). The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: December 26, 2023
    Inventors: Glenn Dranoff, Ryan Sullivan, Matthew Vanneman
  • Publication number: 20230383298
    Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.
    Type: Application
    Filed: January 3, 2023
    Publication date: November 30, 2023
    Applicants: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
  • Publication number: 20230302155
    Abstract: Aspects of this disclosure relate generally to the use of biomaterials for the in vivo generation of CAR expressing cells. In some embodiments, the biomaterials comprise one or more of a cell recruitment composition, a viral vector, and/or a cell activation agent.
    Type: Application
    Filed: August 20, 2021
    Publication date: September 28, 2023
    Inventors: Sandeep Tharian Koshy, Glenn Dranoff, Maria Anna Sofia Broggi, Chris Bridgeman, Stephen Michael Canham, Yoel Melles, Regis Cebe, Brian Walter Granda, Louise Mary Treanor, Shyamali Jayashankar, Jennifer Yang, Amy Rayo, Andrew Patrick Price, Darko Skegro, Justine Guyot, Tushar Dattu Apsunde, Cameron Chuck-munn Lee, Michael Bardroff, Sandra Miller
  • Publication number: 20230256017
    Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.
    Type: Application
    Filed: February 26, 2021
    Publication date: August 17, 2023
    Inventors: Jennifer BROGDON, Glenn DRANOFF, Michael R. GREENE, Anniesha HACK, Olja KODRASI, Elizabeth Dorothy PRATICO, Andrew PRICE, Andrew Marc STEIN, Amy RAYO, Jennifer YANG, Brian Walter GRANDA, Attilio BONDANZA, Boris ENGELS, Hyungwook LIM, Akash SOHONI, Louise TREANOR, Xu ZHU, Carla GUIMARAES, Shyamali JAYASHANKAR, Sandeep Tharian KOSHY, Regis CEBE, Michael BARDROFF, Sandra MILLER
  • Publication number: 20230174933
    Abstract: This disclosure provides methods of making immune effector cells (for example, T cells, NK cells) that comprise (i) a nucleic acid molecule that encodes a controllable chimeric antigen receptor (CCAR) or (ii) a nucleic acid molecule that encodes a CAR and a regulatory molecule, and compositions generated by such methods.
    Type: Application
    Filed: February 26, 2021
    Publication date: June 8, 2023
    Inventors: Jennifer BROGDON, Seth CARBONNEAU, Glenn DRANOFF, Michael R. Greene, Anniesha HACK, Marc Horst Peter HILD, Olja KODRASI, Elizabeth Dorothy PRATICO, Andrew PRICE, Andrew Marc STEIN, Attilio BONDANZA, Boris ENGELS, Carla Patricia Pinto GUIMARAES, Hyungwook LIM, Sujata SHARMA, Akash SOHONI, Louise TREANOR, Xu ZHU
  • Patent number: 11624093
    Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint inhibitor therapies.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: April 11, 2023
    Assignees: Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Kwok-Kin Wong, Chunxiao Xu, Christine F. Brainson, Carla F. Kim, Glenn Dranoff, Peter Hammerman
  • Patent number: 11597934
    Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: March 7, 2023
    Assignees: DANA FARBER CANCER INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION
    Inventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
  • Publication number: 20230039109
    Abstract: Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.
    Type: Application
    Filed: March 15, 2022
    Publication date: February 9, 2023
    Inventors: Bianka Prinz, Jerry M. Thomas, Ansgar Brock, Viviana Cremasco, Catherine Anne Sabatos-Peyton, Glenn Dranoff, Scott Chappel, Andrew Lake, Alison Paterson, Rachel W. O'Connor, Michael Warren, Pamela Holland, Kulandayan Kasi Subramanian, Helena Marie-Louise Fjaellskog, Dirksen Bussiere, Mikias Woldegiorgis, Wei Shu, John Delmas Venable, III, Michael Gladstone, Jonathan Hill, Christine Miller
  • Publication number: 20230013364
    Abstract: Combination therapies comprising antibody molecules that specifically bind to PD-1 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.
    Type: Application
    Filed: December 13, 2021
    Publication date: January 19, 2023
    Inventors: Glenn Dranoff, Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Publication number: 20220364055
    Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.
    Type: Application
    Filed: August 30, 2019
    Publication date: November 17, 2022
    Inventors: Louise Treanor, Michael R. Greene, Jennifer Brogdon, Boris Engels, Glenn Dranoff, Olja Kodrasi, Hyungwook Lim, Akash Sohoni, Elizabeth Dorothy Pratico, Anniesha Hack, Aida Abujoub, Tony Fleming, Lu Huang, Connie Hong, John Blankenship, Brian Holmberg, Chonghui Zhang, Dexiu Bu, Andrew Price, Xu Zhu, Andrew Stein, Attilio Bondanza
  • Publication number: 20220296581
    Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
    Type: Application
    Filed: June 6, 2022
    Publication date: September 22, 2022
    Applicants: NOVARTIS AG, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Leigh ZAWEL, Christopher S. STRAUB, Brant G. FIRESTONE, Glenn DRANOFF, Michael DOUGAN
  • Patent number: 11382905
    Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: July 12, 2022
    Assignees: NOVARTIS AG, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Leigh Zawel, Christopher S. Straub, Brant G. Firestone, Glenn Dranoff, Michael Dougan
  • Publication number: 20220153835
    Abstract: Combination therapies comprising antibody molecules that specifically bind to LAG-3 are disclosed. The combination therapies can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
    Type: Application
    Filed: September 30, 2021
    Publication date: May 19, 2022
    Inventors: Glenn DRANOFF, Frederic TRIEBEL, Chrystelle BRIGNONE, Walter A. BLATTLER, Jennifer Marie MATARAZA, Catherine Ann SABATOS-PEYTON, Hwai Wen CHANG, Gerhard Johann FREY
  • Publication number: 20220133889
    Abstract: Combination therapies comprising antibody molecules that specifically bind to TIM-3 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.
    Type: Application
    Filed: September 17, 2021
    Publication date: May 5, 2022
    Inventors: Glenn Dranoff, Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • Publication number: 20220002382
    Abstract: Methods for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising an NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
    Type: Application
    Filed: April 2, 2021
    Publication date: January 6, 2022
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Glenn Dranoff, Matthew Vanneman, Gordon Freeman
  • Publication number: 20210284737
    Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Application
    Filed: October 23, 2020
    Publication date: September 16, 2021
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Gerhard Johann Frey, Hwai Wen Chang, Jennifer Marie Mataraza, Glenn Dranoff